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Surgical attitudes to blood vessels through the
millennia andleading up to the middle ofthetwentieth
century were, with anecdotal exceptions, limited to
life-saving cautery or ligation. The practice of
vascular surgery was initiated only in the fifties when
arteries and veins - these vasa vitae or vessels oflife -
were deliberately sought out and reconstructed.
Keeping the channels open in order to preserve life, to
revitalise an organ or to salvage a limb has been the
raison d'etre ofthe vascular surgeon. The objectives of
surgical intervention are also its rewards.
The fun and the reward of vascular surgical practice
lies in the challenge of dealing with patients with
major cardiovascular and other risk factors, in the
precision of operative technique and in the generally
gratifying outcomes, tempered on occasion by the
experience offailure. Itis a specialty which has grown
enormously in the range and complexity ofprocedures
undertaken. Over a third of the large numbers treated
require emergency attention. The ubiquitous presence
of diseased blood vessels makes for refreshing
changes of clinical and operative scene and also
accounts forthe close links between vascular surgeons
and other doctors. These fortuitous associations
generate varied interdisciplinary research pro-
grammes which not only straddle the neat boundaries
of prescribed research groupings but also extend
outwards to the sciences, engineering and so on. It is
exactly such collaborative vascularresearch which has
enriched ourknowledge ofthe microcirculation, led to
advances in haemodynamic monitoring, introduced
the concept of the non-invasive ultrasound
investigation, stimulated prosthetic graft development
and brought about innovations in surgical
instrumentation.
During the seventies, the broadening repertoire of
exciting operative procedures in this relatively young
specialty, in personal terms, proved both captivating
and timely. My objective on being appointed to the
very firm where the distinguished surgeons Mr
SinclairIrwin andthe lateMrReginaldLivingstonhad
once been my mentors, was the conversion of a
general surgery unit with 11% vascular throughput
into a dedicated, regional vascular centre and to set up
a clinical vascular laboratory. This process of
engineered metamorphosis was entirely in keeping
with the best progressive traditions of the Royal
Victoria Hospital wherein interlinking specialties have
evolved to create a favourable milieu for clinical care
and research.
This Vascular Surgery Unit at the Royal, one of the
first of three or four such centres in the British Isles,
has contributed to vascular research and specialist
development at international level for two decades.
The vascular service at the Royal relies on the
combined expertise ofvascular surgeons, radiologists,
anaesthetists, nursing staff and laboratory personnel.
This teamprovides atertiary regional service covering
the entire spectrum ofvascular disease.
In a very busy clinical vascular laboratory, over 4,000
studies are undertaken annually. The Vascular Surgery
Unit is licensed to provide specialist vascular training
over the final two-year span. In research it is
represented on national bodies and is also involved in
international projects. A regional Northern Ireland
Vascular Registry (NIVASC), in which other vascular
surgeons in the province participate, is in its second
year of operation and joins half-a-dozen other such
national registries extant in Europe. The Royal
Victoria Hospital, with its clinical profile and facilities
is well placed to meet the challenges at the threshold
ofthe new millennium.
Ifthese vivid lines from Shakespeare
'...but when we have stuffed
Thesepipes and these conveyances ofour blood
With wine andfeeding, we have suppler souls
Than in ourpriest-likefasts...'
Menenius
Coriolanus V.1.
seem to extol the spiritual dividends of gluttony, then
they also appear a trifle prescient about recent
knowledge ofthe health-giving properties ofred wine.
On the other hand, they do not, by any stretch of the
imagination, demonstrate an understanding ofthe best
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way of escaping the onset of atherosclerosis. That
knowledge, relatively recently acquired, is being
accelerated by crucially important observations which
will undoubtedly shape therapeusis in the early years
ofthe next millennium.
New information is constantly expanding our
knowledge of the pathophysiology of injury to the
arterial flow surface. We now know that fluid shear
stresses promote the release ofplatelet-derived growth
factor (PDGF) and basic fibroblast growth factor
(bFGF)' and regulate the expression of adhesion
molecules,2 all of which have pathophysiological
relevance to the process of development of intimal
hyperplasia. Equally, the epidemiology and
pathogenesis ofatherosclerosis is being unravelled by
the addition of new pieces to a complex jigsaw. In
studies at the Karolinska, autoantibodies against
oxidised LDL,3 endothelial cells and cardiolipin4 were
found to be associated with early onset of peripheral
arterial disease. An Australian group has shown that
raised serum lipoprotein(a) in association with
elevated LDL cholesterol is a significant determinant
of the extent of carotid atheroma.5 The spotlight on
elevated homocysteine as a risk factor in the
progression, not only of premature and widespread
arterial disease but, interestingly, also of venous
thrombosis,6 may in future merit its inclusion in the
routine thrombophilia screen. The observed dose-
dependent atherogenic effects of alcohol consumption
on carotid arteries7 may give pause to the current
enthusiasm for a prophylactic glass ofwine.
The complex morphogenesis of the fibrous cap on an
atherosclerotic plaque eventually leading to erosion
and the dangerous consequences of plaque
haemorrhage, rupture and thromboembolism has
caught the imagination of investigators on both sides
of the Atlantic. The accumulation of activated mast
cells around the fibrous cap8 and the production of
matrix-degrading metalloproteinases (MMPs) which
induce collagen breakdown destabilise the fibrous
cap,9 the thinness of which determines its
vulnerability. A fibrous cap at such risk, can now be
detected by 'attenuation-slope mapping'. of plaque
using a sophisticated intravascular ultrasound probe.'0
The discovery of Chlamydia pneumoniae in
atherosclerotic plaque" and a possible causal
relationship is a fascinating mystery which awaits
clarification.
The landmark Scandinavian Simvastatin Survival
Study (4S) convincingly proved that the lowering of
cholesterol prolongs life in patients with established
coronary artery disease.'2 Clinical research reports of
the value of pravastatin, lovastatin, and other statins
leave one with the impression that a specific statin
attuned to eachpermutation oflipid abnormalities will
probably come on line. The exciting observation of
carotid plaque regression in women receiving
oestrogen replacement therapy'3 offers a seductive
avenue for a large-scale controlled study, the
practicalities of which are already under
consideration. Vast quantities of research data in this
area are accumulating which will catalyse the
development of new modalities of treatment aimed at
arresting and reversing the march of atherosclerosis.
In the years ahead, moleculargenetic and gene therapy
will be mobilised in the task of vitiating major risk
factors such as hyperlipidaemic disorders and
diabetes, both of which accelerate the advance of
arterial disease. Recombinant DNA technology has
already been used experimentally to modify
endothelial and vascular smooth muscle cell
expression.'4 In this way, intimal hyperplasia
developing at prosthetic graft anastomoses with the
host artery, mightbe suppressed sufficiently toprevent
occlusion of the lumen and graft failure. In time,
miniaturised endovascular delivery techniques might
well be employed to treat a particular diseased
segment of artery but before that goal is realised
several hurdles of technique, safety and efficacy in
using gene therapy will have to be faced.
New operative techniques will undoubtedly herald the
new millennium but their implementation should be
dependent on objective appraisal. In the past, vascular
operations originated in three main ways: through
argument based on knowledge ofthepathophysiology,
empirically through successful experiment or on the
strength ofresults of a controlled trial, and thirdly, on
the pragmatic basis that it works.'5 Thus a priori
knowledge that emboli from carotid plaque and
thrombus produced acute neurological and ocular
events, persuaded surgeons to proceed with carotid
endarterectomy. Around the world, excessive zealby a
few to operate even when the case for surgery was not
convincing, has been matched by the therapeutic
nihilism of some neurologists grounded on the
Descartian assertion that carotid artery disease as such
did not exist. The North American Symptomatic
Carotid Endarterectomy Trial (NASCET)16 and the
European Carotid Surgery Trial (ECST)'7
simultaneously concluded that surgery for
symptomatic carotid stenosis of 70% or more was
preferable to best medical treatment in reducing the
rate of stroke and mortality. That position is founded
C) The Ulster Medical Society, 199880 Vascular Surgery
on the presumption that selection of patients follows
careful assessment and that surgical technique is
meticulous. The advantage of patch angioplasty in
reducing the incidence of recurrent stenosis has been
increasingly appreciated.'8 Transcranial Doppler
monitoring of middle cerebral artery flow
perioperatively provides objective assurance of the
safety ofsurgery. Surgeons should continue toperform
this operation only if their audited morbidity and
mortality figures remain within the bounds of best
reported practice.
It is predicted that two major international trials into
which I have entered cases, namely the Asymptomatic
Carotid Surgery Trial (ACST) and the Asymptomatic
Carotid Stenosis Risk of Stroke (ACSRS) Study will
provide important answers. The former is likely to
confirm that surgery, in good hands, is preferable to
best medical treatment, while the latter is likely to
show that certain plaque characteristics are associated
with a higher incidence of stroke. Certainly,
accumulating evidence ofthe natural history ofcarotid
atheroma would lead one to anticipate the
recommendation that surgery is worthwhile even in
the asymptomatic carotid patient.
Diagnostic imaging of the cerebrovascular tree has
evolved over the years. Carotid angiography which
carries a small but finite risk has been displaced to
some extent by colour flow Duplex scans. It must be
admitted, however, that during the occasional carotid
operation one would have given anything for a set of
clear cerebrovascular angiography films in place of
the necessarily limited ultrasound image.
Nevertheless, it is not just the image or the flow data
but the capacity of the Duplex scan to characterise
plaque, in terms ofechodensity or more unstable
echolucency, which has enhanced its popularity.
Precise computer-assisted plaque characterisation will
eventually be the norm in evaluating the degree of
plaque instability.
Evidence-based treatment supported by sustained
audit of outcome should be the touchstone of ideal
vascular practice. Acute carotid ischaemic stroke
represents a scenario which challenges the clinician to
act quickly to prevent disaster. The American trial of
intravenous tissue plasminogen activator (pt-PA)
aimed at arterial clot lysis within three hours of onset
of stroke resulted in 30% of patients having minimal
disability ornone atthreemonths, butthe dilemmalies
in the knowledge that this benefit was bought at the
cost of a 6.4% incidence of symptomatic intracranial
haemorrhage.'9 The results of the European Co-
operative Acute Stroke Study (ECAS) and that of an
Italian trial have been comparatively discouraging, but
further study in this area is bound to continue.
In the United States the activities of many
cardiologists have been attenuated in the wake of
constraints placed by the flourishing HMO systems.
Not to be outdone by such reversals, some of them
have mobilized their costly, but otherwise redundant
equipment, to perform angioplasties and stenting
procedures on patients with carotid artery disease. The
assessment and selection of these patients for
treatment and the outcomes, however, ought to be
submitted to the detailed scrutiny generally accorded
to carotid endarterectomy by vascular surgeons. If
carotid angioplasty is to gain acceptance, data based
on standardised protocols must first be produced and,
if deemed appropriate, a randomised double-blind
controlled trial comparing it with carotid
endarterectomy should follow.
Severe vertebrobasilar insufficiency (VBI) has
hitherto received scant surgical attention but
operations to improve vertebral artery flow are being
undertaken more often. A detached distal vertebral
artery may be transposed directly into the common
carotid artery or, alternatively, a skeletonised external
carotid artery may be mobilised and anastomosed to
the distal vertebral artery.
The quality of surface ultrasound in revealing plaque
on the walls of the arch of the aorta and great vessels
has been superseded by transoesophageal
echocardiography(TOE) which, being safe, portable
and accurate, may become the investigation ofchoice
in acute traumatic aortic disruption. Data
reconstruction from spiral CT scans already provides
3-D images of aortic dissection and of thoraco-
abdominal aneurysms. Both (TOE) and the more
invasive technique of intravascular ultrasound will
continue to compete with CT in the diagnosis of
thoracic aortic dissection.
Operative reconstruction of the great vessels for
atheroma or Takayasu's disease, aimed at preventing
stroke, blindness, and upper limb ischaemia, will still
be necessary. The occasional practice of balloon
angioplasty ofstenotic lesions atthe origin ofthe great
vessels is not risk-free. The safety margins in surgery
for thoraco-abdominal aneurysms have slowly
improved: a mortality rate of5% and a paraplegia rate
of 1.5% reported from Houston by Joseph Coselli can
hardly be excelled.20 Epidural spinal cord protection,
increasing preference for a 'clamp-and-repair'
approach and the selective use of partial bypass may
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have contributed to a better outcome.
Endovascular repair of infrarenal aortic aneurysms
was perceived as an exciting development in that it
offered an alternative form of treatment for the high
risk patient with the added bonus ofa shorter stay. 3-D
multiplane reformats from spiral CT scans and virtual
reality software can be used to plan the procedure.
James May ofSydney, a key exponent, acknowledges
that the technique creates its own problems.21 Two
major operative risks are micro-embolisation of clot
from within the aneurysm and failure ofthe procedure
itself requiring conversion to conventional surgery.
Late dangers include delayed rupture, leaks into the
aneurysm sac and even dislodgement of the proximal
end ofthe stent graft as the aorta dilates. Clearly, this
procedure requires to be monitored, but as entry into
available registries is voluntary, failures may go
unrecorded. One clear and recognised indication for
endoluminal stenting is aortic dissection forwhich itis
safer than conventional surgery. Premature
conclusions regarding endoluminal aneurysm repair
places vascularsurgeons underpressure frompotential
consumers, and it has also spawned a proliferation of
competing and sometimes unreliable products. These
influences may induce some surgeons to join the
bandwagon simply to 'enhance' their centres
regardless of the phenomenal expense involved. The
timeless axiomof'primium nonnocere', ie 'firstdo no
harm', ought to be kept in mind before initiating any
change. That can only come after disciplined
evaluation through well controlled studies using
standardized protocols based on an intention to treat.
Progress in technological support is also required and
therefore the precise indications for endovascular
aneurysm repair will become clearer well after the
year 2000.
One apparently simple but elusive question on surgery
for abdominal aortic aneurysms is the optimal
diameter at which operation should be undertaken to
preempt rupture. A recent Canadian study has
confirmed prejudices that aneurysms exceeding 5 cm
diameter require surgery and that intervention in those
of lesser size should depend on their rate of
enlargement. Recent papers have highlighted the
appearances of the 'crescent sign', a high-attenuating
peripheral crescent observed on an unenhanced CT
scan, which signals impending rupture and therefore
demands urgent intervention.22 An increased turnover
ofType Ill collagen in the aneurysm wall23 may reflect
the rate ofdegradation and may turn out to be a useful
marker of the rate of enlargement. Research into
elastin cross-linking, collagen, and the importance of
elastase andcollagenase in aneurysm wall activity will
probably continue in desultory fashion well into the
next century. A few surgeons have attempted
laparoscopic aorto-iliac surgery: this expensive and
potentially disastrous procedure which requires up to
seven ports and lasts approximately 7-8 hours has
little hope of being accepted in the forseeable future.
Surgery for renal artery stenosis, for both ostial and
non-ostial atherosclerotic lesions as well as for
fibromuscular hyperplasia, has been replaced almost
completely by balloon angioplasty and stent insertion
but we must keep our eye open for recurrent stenosis
in the longer term. An interventional approach also
bodes well for the management of symptomatic
mesenteric arterial lesions.
Hypercoagulability is observed in up to 40% of
vascularpatients although the nature ofthe underlying
problem is not always identified with ease. Factor V
resistance to activated protein C, attributable to a
single point mutation is now recognised as the most
frequent offender.24 Undoubtedly other such
abnormalities will come to light. Catheter-guided
intra-arterial thrombolysis has secured its place in the
management of some patients presenting with an
acutely ischaemic limb. In acute occlusion of bypass
grafts, lytic therapy, sometimes as aprelude to balloon
or operative angioplasty, is also well established.
Nonetheless, in either instance, ifthe vascular surgeon
believes that the time taken for effective lysis will
compromise viability, he should proceed immediately
to surgery.
Angioscopically-directed thrombo-embolectomy is an
attractive technique in ensuring more complete
clearance of clot but its application may wane as
intraoperative adjuvant thrombolytic techniques
become more refined and less frequently complicated
by bleeding, stroke, ischaemia-reperfusion injury,
limb loss and even mortality.25 Using the isolated
thrombolysis perfusion technique pioneered by Tony
Comerota of Philadelphia,26 effectively high local
levels can be attained while the risks of systemic
problems remain negligible. In resolving doubt as to
the viability of ischaemic muscle, positron emission
tomography (PET) scans using [18F] fluoro-2-
deoxyglucose (FDG) uptake have shown high
accuracy27 but this innovative approach is very
cumbersome andforthepresenthas toremain no more
than a research tool.
The severely disabled claudicant deserves bypass
surgery but in the ordinary case doctors are drifting to
promising exercise rehabilitation programmes.
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Carnitine (propionyl-L-carnitine), a naturally
occurring compound, whichremoves excess acetyl co-
enzyme A and improves oxidative metabolism, is
especially effective in claudication and may become a
valuable adjuvant.28 Even more intriguing has been the
experimental demonstration ofthe biological response
to ischaemia of angiogenesis or neovascularisation in
which the mitogenic potential of acidic fibroblast
growth factor (aFGF) can be enhanced by heparin
which is a cofactor for aFGF.29 The possible clinical
impact of accelerating the development of collateral
flow using this concept of 'therapeutic' angiogenesis
in patients with limb ischaemia ought to become
clearer during the next decade.
The large calibre Dacron graft used in aorto-femoral
bypass operations represents an unparalleled success
story for lengthy occlusions. Balloon angioplasty,
possibly along with stenting, works well in a good
proportion of short-segment iliac occlusive lesions. In
the femoro-popliteal region the success rate of
angioplasty is modest and it often has to be repeated;
whereas vein bypass grafts of short length have the
best patency rates on record and ought to be the first
line of treatment. At infrageniculate level angioplasty
tends to be no more than a temporising measure. In
general, however, the vascularradiologistisproving to
be an increasingly valuable ally in the battle to keep
the channels open. Stent grafts of
polytetrafluoroethylene to replace lengthy femoro-
popliteal occlusions is a new but rather clumsy
solution to a problem eminently dealt with by the
vascular surgeon. Fortunately, as in the past, many
such innovations become fashionable but fail to
displace well tried operations and are consigned
swiftly to the waste-bin ofobsolescence.
Femoro-distal bypass surgery in patients with critical
lower limb ischaemia, many ofthemwith diabetes and
some with Buerger's disease, have been rewarded by
improving rates of limb salvage. After over two
decades of disillusionment with a variety of small-
calibre prosthetic grafts surgeons are turning
increasingly to the original gold standard of
autogenous vein, harvesting it from the upper limb if
necessary. In-situ vein grafts orunreversed vein grafts,
the valves of which require to be disrupted by a
valvulotome, allow a better match ofcalibre ofvein to
host vessel at each end and therefore became popular
inlongbypasses. This technique ofveingrafting led to
the introduction of myriad techniques for disabling
vein valves, including angioscopically-guided
valvulotomy. After mature reflection and having noted
the incidence of failure, especially of small-diameter
in-situ bypass grafts, vascular surgeons are showing a
renewed faithinthewell-tried andtestedreversedvein
graft. In the anastomotic field, fine clips may in time
replace polypropylene suture while fibrin glues and
sealants which reduce suture line bleeding are now
available. Spinal cord stimulation is being used in an
attempt to relieve pain in extreme cases oflower limb
ischaemia but this expensive device should not be
used indiscriminately until it is first subjected to the
rigours ofa randomised trial.
Surveillance of limb bypass grafts using colour flow
Duplex scans to pick up early signs ofstenosis in vein
grafts or of intimal hyperplasia at prosthetic graft
anastomoses has been one ofthe many functions ofthe
clinical vascular laboratory. These changes, usually
discovered in a modest proportion of cases within a
year of implantation, allow the opportunity for
corrective surgery to preempt graft failure. There is
much debate on the value of ultrasound surveillance
but the view is held, not surprisingly from the cold-
blooded perspective ofcost-effectiveness, that it is not
worth while. It should be appreciated that prompt
intervention to prolong graft patency can save a limb,
and alsothatearlypostoperative evidence ofnormality
of a graft does not bestow perpetual patency on it.
Much more desirable, of course, is an effective
deterrent against intimal hyperplasia. Vascular
literature is replete with reports on restenosis of
arterial grafts and the complex pathophysiological
mechanisms involved in smooth muscle cell
proliferation andmatrixdeposition observed inintimal
hyperplasia. Various drugs such as heparin, calcium
channel blockers and angiotensin-converting enzyme
(ACE) inhibitors have been employed to discourage
this process. Less appealing strategies include the
interposition of vein cuffs and collars between
prosthesis and host artery, and the more disturbing
measure of intravascular low-dose irradiation.
Encouraging research work using matrix
metalloproteinase activity inhibitors,30 photodynamic
therapy3' and others await the test oftime.
Low molecular weight heparin (LMWH) is safe,
effective and convenient and has almost completely
displaced the use ofunfractioned heparin in deep vein
thrombosis prophylaxis. The peroperative physical
measures of intermittent pneumatic compression of
the calfusedby some surgeons is being superseded by
the surprisingly effective impulse foot-pump. In acute
deep vein thrombosis, colour flow Duplex scans ofthe
major channels are accurate and informative but
venography will still remain important in the detailed
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imaging of calf vein tributaries. Advances in MRA
technology will in due course offer a fresh alternative
to current diagnostic imaging of the venous system.
Thrombolysis in instances of ilio-femoral vein
thrombosis perhaps protected by a caval filter has the
attractive potential for clearing clot early enough to
preserve valve function while also expediting
discharge from hospital. When contraindications to
lysis exist, surgical thrombectomy and construction of
a temporary arteriovenous fistula is the best available
alternative.32
In the management of post-thrombotic lower limb
venous hypertension, valve reconstruction and valve
transposition techniques have been refined and will be
increasingly applied. The durability of the much-
vaunted technique ofendoscopic subfascial ligation of
incompetent perforators in promoting ulcerhealing, so
far unproven, can only be established by a proper
controlled trial. In vein trunk compression syndromes,
usually a feature of advanced cancer, stents carefully
placed by the skilled interventional radiologist have
brought profound relief.
Management of the non-operative aspects of vascular
disease, which in this country is largely the
responsibility ofthe vascular surgeon, falls within the
discipline of angiology, a specialty which has been
successfully nurtured in several European countries.
Some angiologists even undertake interventional
vascular procedures, a technical role which in most
British centres is exercised by our radiology
colleagues. This collaborative relationship between
vascular surgeons and radiologists is set fair for the
next millennium as long as it is rooted on the
immutable premise that optimal care of the vascular
patient as a whole remains the pre-eminent
consideration. A case should be made for the
enlargement ofthis team to include a physician with a
specific interest in vascular disease.
Looking ahead to the future of vascular surgery one
could concievably become preoccupied rather
fruitlessly by the inequities and the underfunding of
health care in general. These concerns however, seem,
ephemeral, particularly when viewed against the ethos
of service, immeasurable devotion, compassion,
sacrifice and, not least, the optimism, which have
steered this great hospital through two long centuries,
and which will doubtless sustain it in the years to
come.
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